Abstract 17886: Impact of a Very Early Invasive Strategy in High Risk NSTEMI: Analysis From the TAO (Treatment for Acute Coronary Syndromes With Otamixaban) Trial

Introduction: In patients with NSTEMI and GRACE score > 140, coronary angiography (CAG) with a view to revascularization is recommended within 24h. Whether further reducing time to CAG is beneficial in this population remains unclear. Hypothesis: We sought to compare the impact of a “very early” (i.e. within 12 hours after admission), early (12-24h) and standard (>24h) CAG in patients hospitalized for NSTEMI and with GRACE score >140. Methods: The TAO trial randomized individuals with moderate to high-risk NSTEMI and CAG scheduled within the first 72 hours to heparin plus eptifibatide versus otamixaban. Otamixaban did not reduce the rate of ischemic events but did increase bleeding. Patients with GRACE score > 140 and undergoing CAG were stratified in 3 groups according to timing of CAG from the first ECG performed on admission (≤12h, 12 to 24h, >24h). The primary outcome was defined by the composite of all-cause death and MI at 180 days. Analyses were adjusted on age, gender, diabetes mellitus, prior PCI...